Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses-Reference-Cited by-同舟云学术

Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses

Published:2023-05 Issue: Volume:561 Page:216139
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Silva-Pilipich Noelia,Blanco Ester,Lozano Teresa,Martisova Eva,Igea Ana,Herrador-Cañete Guillermo,Ballesteros-Briones María Cristina,Gorraiz Marta,Sarrión Patricia,González-Sapienza Gualberto,Lasarte Juan José,Vanrell Lucía,Smerdou Cristian^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference55 articles.

1. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment;Nakamura;Cell. Mol. Immunol.,2020

2. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations;Seidel;Front. Oncol.,2018

3. The future of immune checkpoint therapy;Sharma;Science (80-.),2015

4. Cancer immunotherapy: harnessing the immune system to battle cancer;Yang;J. Clin. Invest.,2015

5. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance;Bagchi;Annu. Rev. Pathol. Mech. Dis.,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity;Antibodies;2024-04-24

2. B7–H1 agonists suppress the PI3K/AKT/mtor pathway by degrading p110γ and independently induce cell death;Cancer Letters;2024-03

3. Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies;British Journal of Cancer;2024-01-09

4. Biomimetic Nano-Drug Delivery System: An Emerging Platform for Promoting Tumor Treatment;International Journal of Nanomedicine;2024-01

5. Local Delivery of Immunomodulatory Antibodies for Gastrointestinal Tumors;Cancers;2023-04-18